Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a malignant tumor with a fairly poor prognosis (5-year survival of less than 50%). Using sorafenib, the only food and drug administration (FDA)-approved drug, HCC cannot be effectively treated; it can only be controlled at most for a couple of months. There is a gre...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2020-12-01
|
| Series: | Liver Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2542568420300593 |
| _version_ | 1818672389116919808 |
|---|---|
| author | Tsung-Chieh Shih Lijun Wang Hsiao-Chi Wang Yu-Jui Yvonne Wan |
| author_facet | Tsung-Chieh Shih Lijun Wang Hsiao-Chi Wang Yu-Jui Yvonne Wan |
| author_sort | Tsung-Chieh Shih |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is a malignant tumor with a fairly poor prognosis (5-year survival of less than 50%). Using sorafenib, the only food and drug administration (FDA)-approved drug, HCC cannot be effectively treated; it can only be controlled at most for a couple of months. There is a great need to develop efficacious treatment against this debilitating disease. Glypican-3 (GPC3), a member of the glypican family that attaches to the cell surface by a glycosylphosphatidylinositol anchor, is overexpressed in HCC cases and is elevated in the serum of a large proportion of patients with HCC. GPC3 expression contributes to HCC growth and metastasis. Furthermore, several different types of antibodies targeting GPC3 have been developed. The aim of this review is to summarize the current literatures on the GPC3 expression in human HCC, molecular mechanisms of GPC3 regulation and antibodies targeting GPC3. |
| first_indexed | 2024-12-17T07:39:07Z |
| format | Article |
| id | doaj.art-a9f16afa5be147538113171dd52a2c80 |
| institution | Directory Open Access Journal |
| issn | 2542-5684 |
| language | English |
| last_indexed | 2024-12-17T07:39:07Z |
| publishDate | 2020-12-01 |
| publisher | KeAi Communications Co., Ltd. |
| record_format | Article |
| series | Liver Research |
| spelling | doaj.art-a9f16afa5be147538113171dd52a2c802022-12-21T21:58:13ZengKeAi Communications Co., Ltd.Liver Research2542-56842020-12-0144168172Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinomaTsung-Chieh Shih0Lijun Wang1Hsiao-Chi Wang2Yu-Jui Yvonne Wan3Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA, USADepartment of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA, USADepartment of Internal Medicine, University of California Davis, Davis, CA, USADepartment of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA, USA; Corresponding author. Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA, USA.Hepatocellular carcinoma (HCC) is a malignant tumor with a fairly poor prognosis (5-year survival of less than 50%). Using sorafenib, the only food and drug administration (FDA)-approved drug, HCC cannot be effectively treated; it can only be controlled at most for a couple of months. There is a great need to develop efficacious treatment against this debilitating disease. Glypican-3 (GPC3), a member of the glypican family that attaches to the cell surface by a glycosylphosphatidylinositol anchor, is overexpressed in HCC cases and is elevated in the serum of a large proportion of patients with HCC. GPC3 expression contributes to HCC growth and metastasis. Furthermore, several different types of antibodies targeting GPC3 have been developed. The aim of this review is to summarize the current literatures on the GPC3 expression in human HCC, molecular mechanisms of GPC3 regulation and antibodies targeting GPC3.http://www.sciencedirect.com/science/article/pii/S2542568420300593Glypican-3 (GPC3)Wnt signalingHepatocellular carcinoma (HCC) |
| spellingShingle | Tsung-Chieh Shih Lijun Wang Hsiao-Chi Wang Yu-Jui Yvonne Wan Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma Liver Research Glypican-3 (GPC3) Wnt signaling Hepatocellular carcinoma (HCC) |
| title | Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma |
| title_full | Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma |
| title_fullStr | Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma |
| title_full_unstemmed | Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma |
| title_short | Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma |
| title_sort | glypican 3 a molecular marker for the detection and treatment of hepatocellular carcinoma |
| topic | Glypican-3 (GPC3) Wnt signaling Hepatocellular carcinoma (HCC) |
| url | http://www.sciencedirect.com/science/article/pii/S2542568420300593 |
| work_keys_str_mv | AT tsungchiehshih glypican3amolecularmarkerforthedetectionandtreatmentofhepatocellularcarcinoma AT lijunwang glypican3amolecularmarkerforthedetectionandtreatmentofhepatocellularcarcinoma AT hsiaochiwang glypican3amolecularmarkerforthedetectionandtreatmentofhepatocellularcarcinoma AT yujuiyvonnewan glypican3amolecularmarkerforthedetectionandtreatmentofhepatocellularcarcinoma |